Incomplete informed consent for psychotropic medications
Summary
The facility failed to ensure residents receiving psychotropic medications were educated on the risks and benefits of those medications and that informed consent was obtained from the resident and/or representative before use. This deficiency affected five of five residents reviewed for unnecessary medications: Resident #1, Resident #5, Resident #27, Resident #30, and Resident #35. Resident #35 had diagnoses including schizo-affective disorder, bipolar disorder, and anxiety disorder and was receiving aripiprazole, lorazepam, trazodone, and desvenlafaxine. Her EMR did not contain signed consents for psychotropic medication use, and there was no evidence she had been educated on the risks and benefits of the medications. The DON confirmed there was no documented evidence of informed discussion or signed consent, and the SSD stated she did not have signed consents. A consent later provided by the facility was obtained only after the DON was asked about it, and it listed only the resident’s signature and date without identifying the medications, diagnoses, or risks and benefits. Resident #5 had diagnoses including major depressive disorder and other significant medical conditions, and the MDS showed moderately impaired cognition. She was receiving aripiprazole, sertraline, and trazodone. Her consent form for psychoactive medication use was signed, but the sections indicating that she had been informed of and understood the reason for and risks of use were blank, and the medication and diagnosis sections were also blank. Resident #30 had diagnoses including dementia, anxiety disorder, and schizophrenia, with severely impaired cognition on the MDS, and was receiving escitalopram, mirtazapine, and buspirone. Her EMR contained no evidence of the facility’s psychoactive medication consent form, and the DON confirmed there was no documented evidence of education or signed consent. Resident #1 had a BIMS score of 15 and required total dependence for ADLs. He was prescribed paroxetine, but the informed consent form for psychoactive medication use had blank sections for the resident’s understanding of the reason for and risks of use, as well as the diagnosis. Resident #27 had a BIMS score of 13 and was prescribed duloxetine and buspirone, with additional monitoring orders for antidepressant effects and serotonin syndrome. His consent form was signed, but the medication, diagnosis, and witness sections were incomplete, and the DON confirmed there was no documented evidence that he had been informed of the risks and benefits associated with the psychotropic medications he was receiving. The facility policy required residents, families, or representatives to be informed of the benefits, risks, and alternatives before initiating or increasing psychotropic medications, including black box warnings for antipsychotics.
Penalty
Resources
Below are regulatory guidelines relevant to this citation:
Trusted data from CMS and state health departments
Every citation, penalty and Plan of Correction is sourced from public CMS records (latest release July 29, 2026) and official state health department websites — never guesswork.
In your survey window? See what surveyors are citing.
The Survey-Prep Report maps your facility's risk from 12 months of CMS and state citation data — what's being cited around you and what to check first. $129 one-time.